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Abstract
The adaptive immune system of placental mammals has evolved to tolerate the fetus. Rejection of
the fetus by adaptive immune responses is therefore a rare event, with abortion being caused more
frequently by inflammation in the placenta. This review will cover recent aspects of immune
privilege and the innate immune system at the feto-maternal interface, citing examples of the role
played by microbial infections in fetal demise.
Introduction
Placental mammals have been subjected to two opposing
selective pressures during evolution, as survival of the spe-
cies depends on the ability to eliminate microbial patho-
gens while at the same time protecting fetuses from
immune rejection. In this respect, it is noteworthy that
placentation had to evolve in animals that already pos-
sessed a major histocompatibility complex (MHC). One
could therefore speculate that the innate immune system
at the feto-maternal interface underwent less stringent
selective pressures to ensure quick and efficient local pro-
tection against infection, while the adaptive immune sys-
tem had to remain under full control to prevent rejection
of the semi-allogeneic fetus. Given the high selective pres-
sures at work, pregnancy failures unequivocally related to
immune dysregulation are therefore rare events, whether
in the human species or laboratory animals. Conversely,
there are many examples of abortion or fetal distress due
to placental inflammation and/or infection.
A number of excellent reviews have been published
recently on adaptive immune responses during pregnancy
[1-6]. The local activation of some components of the
innate immune system at the feto-maternal interface is
attracting a growing interest from the reproductive immu-
nology community. This review will emphasize aspects of
the innate immune system that could contribute to repro-
ductive failure.
Immune privilege at the feto-maternal interface
Apoptosis can be triggered by the Th1 cytokine, TNFα, or
the Fas ligand (Fas-L). As human syncytiotrophoblasts
and cytotrophoblasts in placental villi and chorionic
extravillous trophoblasts produce the Fas-L, it has been
proposed that trophoblast Fas-L may contribute to placen-
tal immune privilege during pregnancy by promoting
apoptosis of activated, Fas-bearing maternal lymphocytes
at the feto-maternal interface (Fig. 1). This view is sup-
ported by studies with isolated human peripheral blood
lymphocytes co-cultured with trophoblasts [7], but the
data are less clear in animal models. The lpr mutation
(defect in the function of Fas) had no effect on the out-
come of pregnancy; but gld mice (lacking functional Fas-
L) displayed extensive leukocyte infiltrates and cell death
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at the decidual-placental interface, and delivered small lit-
ters [8].
Some newly-discovered co-stimulatory molecules of the
B7 family, such as B7-H1, can induce T cell apoptosis (Fig.
1). However, they can also deviate immune responses
towards a Th2 phenotype, and these molecules are appar-
ently present in the placenta [9]. Thus, the roles played by
the Fas-L and the B7 family molecules in immune privi-
lege at the fetal-maternal interface needs to be re-evalu-
ated, especially given the possibility that the B7 molecules
may affect local Th2 cytokine production.
It was thought that the main function of HLA-G may be to
inhibit the cytolytic activity of maternal NK cells, but this
function is being reappraised [10]. HLA-G may also inter-
act with decidual macrophages at the feto-maternal inter-
face, perhaps altering the profile of macrophage cytokine
production (Fig. 2). The leader peptides of nascent HLA-G
proteins are presented efficiently by HLA-E molecules,
thus enhancing cell surface expression of HLA-E, which
interacts with surface receptors on NK cells, macrophages
and a variety of T cell types. One function of HLA-G,
expressed by extravillous trophoblast, may thus be to fine-
tune innate immunity by modulating macrophage func-
tion and indirectly inhibiting the activity of maternal NK
and NK-like cells via HLA-E (Fig. 1) [10]. Recent evidence
suggests that soluble HLA-G1 is immunosuppressive,
induces apoptosis of activated CD8+ T cells and down-
modulates CD4+ T cell proliferation. Moreover, soluble
HLA-G1 could also play a role during implantation [11].
Finally, HLA-G may also be expressed in peripheral tissues
during viral infections and organ transplantion, where it
Trophoblast versus maternal T or NK cell interactions Figure 1
Trophoblast versus maternal T or NK cell interactions. NK: 
natural killer cell.
Schematic illustration of the fetal-maternal interface in  humans and mice Figure 2
Schematic illustration of the fetal-maternal interface in 
humans and mice. The placenta, representing the main inter-
face between the mother and fetus, is composed of two 
parts: the trophoblast of embryonic origin, and the decidua 
of maternal origin. During implantation, the trophoblasts 
derived from the early trophectoderm proliferate rapidly and 
invade, much like tumor cells, the uterine endometrial tissue. 
The cell wall of maternal blood vessels encountered by tro-
phoblasts is degraded, causing trophoblasts to be bathed by 
maternal blood. At the same time, the surrounding maternal 
tissue is modified extensively, leading to the formation of the 
decidua. In the human placenta, the syncytiotrophoblast 
cover of the villi is the main site for all maternofetal transfer 
and secretory functions, and some of the extravillous 
cytotrophoblast migrate to an endovascular location, where 
they can form a new vessel lining, in spiral arteries in particu-
lar [51]. Although many differences can be distinguished at 
the histological level, an increasing number of similarities can 
be found in the cellular and molecular mechanisms involved 
in implantation and placental function [52,53]. Thus, the fetal-
maternal interface comprises two main zones of contact, 
between the fetal trophoblast layers and the maternal 
decidua, or maternal blood. Red arrows indicate the blood 
flow to and from the placenta via maternal arteries or veins, 
respectively. V: villous trophoblast; IVS: intervillous space; 
CMA: mouse central maternal artery; S : spongiotrophoblast; 
L: labyrinthine trophoblast; UC: umbilical cord; MD : mater-
nal decidua.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/121
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may protect the tissues during inflammatory responses by
favoring Th2-type responses [12].
Components of innate immunity at the feto-
maternal interface
Both rodents and higher primates have a hemochorial
placenta, in which fetally-derived trophoblast tissue is
bathed in maternal blood lacunae. The maternal decidua
represents another site of direct contact between fetal tro-
phoblasts and maternal cells (Fig. 2). During pregnancy,
the major cell type found at the site of implantation
within the maternal decidua are the uterine NK cells. The
time-course of their appearance and recent evidence from
NK-deficient mouse models suggests that they play an
important role in implantation [13-15]. Similar cell types
expressing high concentrations of the cytolytic pore-form-
ing protein, perforin, and formerly called "granulated
metrial gland" cells, are found in the murine uterus
[16,17]. Finally, a type of NK cell sharing some properties
with T cells (the NKT cell) is also present and appear to
play an important role in some pregnancy loss (see
below).
Innate immunity during abortion
To the best of our knowledge, there are no convincing
examples showing that the semi-allogeneic fetus is
rejected by the maternal adaptive immune system, in the
same way as it might reject an allogeneic graft. On the con-
trary, experimental evidence indicates that fetal alloanti-
gens are recognized by the maternal adaptive immune
system, but this recognition induces tolerance of specific
maternal T or B cells, as demonstrated in antigen-receptor
transgenic models [18-21]. Instead, most of the current
evidence suggests that inflammation, complement activa-
tion and/or leukocyte infiltration precede abortion. The
events leading to abortion share many of the salient fea-
tures of an innate immune response, such as rapid activa-
tion, little or no specificity, and no memory. Furthermore,
a growing body of evidence from animal models strongly
suggest that abortions are triggered when innate immune
responses or their regulators are perturbed (for reviews,
see [22,23]).
Complement activation, a component of the inflamma-
tory response, leads to necrosis, and uncontrolled com-
plement activation in the placenta results in fetal loss [23].
Clinically, these responses could be triggered by local
necrotic lesions (due to stress or ischemia) or infections of
the placenta. Thus, anti-phospholipid syndrome (APS)
results in recurrent fetal loss occurring in the presence of
anti-phospholipid (aPL) antibodies. Some of these anti-
bodies may target phosphatidylserine (PS) exposed on the
surface of trophoblasts, as shown by both animal and in
vitro models [24]. But complement activation is indispen-
sable for aPL antibody-mediated fetal loss, as the fetuses
are resistant to aPL-induced damage in mice deficient in
complement C3 [25]. Likewise, fetal loss is provoked by a
deficiency in the murine complement regulator, Crry,
which results in complement deposition and placenta
inflammation, and fetuses are rescued from lethality
when Crry-deficient mice are bred to C3-deficient mice.
Along similar lines, semi-allogeneic fetuses are resorbed
after treatment with an indoleamine 2,-3-dioxygenase
(IDO) inhibitor, which triggers extensive inflammation,
complement deposition (even in the absence of
antibodies) and hemorrhagic necrosis at the feto-mater-
nal interface [26].
The enzyme IDO, which degrades tryptophan, is
expressed in syncytiotrophoblasts and macrophages dur-
ing gestation. In vitro, macrophages suppress T cell activity
due to degradation of tryptophan by IDO, and the sup-
pression is reversed by treatment with an IDO inhibitor.
Likewise, the tryptophan concentration is significantly
lower in pregnant women than in nonpregnant controls.
IDO activity appears to protect the fetus by suppressing T-
cell dependent inflammatory responses to fetal alloanti-
gens, since syngeneic fetuses are not rejected after treat-
ment with IDO inhibitor [26]. Thus, trophoblasts and
antigen-presenting cells in the placenta may protect the
fetus via tryptophan catabolism, thus preventing a unique
type of inflammation that involves T cell-dependent, anti-
body-independent complement activation. However,
alternative mechanisms have been proposed to account
for the results obtained with the IDO inhibitor, including
indirect effects of IDO inhibition on vasoconstriction and
macrophage activation [27], and death of T cells due to
release of by-products of the IDO reaction, such as
kynurerine, 3-hydroxykynurenine and 3-hydroxyan-
thranilic acid [28-30].
Xu et al. have elegantly demonstrated the important role
of Crry in the outcome of murine pregnancy [31]. Trigger-
ing of resorptions by administration of IDO inhibitor to
pregnant mice was reported to depend on T cell recogni-
tion of fetal alloantigens in the presence of increased con-
centrations of tryptophan [26]. These resorptions were
subsequently shown to result from local complement acti-
vation and inflammation. More recently, a fascinating
case of serendipity led to the discovery that a deficiency in
the N-terminal domain of TBP (TATA binding protein,
used for promoter recognition during transcription initia-
tion by RNA polymerases) results in a placental malfunc-
tion that triggers inflammation, hemorrhages and
clotting, such that over 90 % of fetuses die in midgestation
[32]. Curiously, the local placental damage was avoided
by rearing the mutant fetuses in RAG-deficient mothers.
Hence, although the precise cellular and molecular path-
ways remain to be elucidated, it is remarkable that the
destruction of the feto-placental units by local innateReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/121
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mechanisms is prevented in the absence of a functional
adaptive maternal immune system.
Stimulation of innate immune responses and 
abortion by microbial infections
Infections of the genital tract of pregnant mothers by
Chlamydia trachomatis,  Neisseria gonorrhoeae, and Tri-
chomonas vaginalis cause a large but undetermined fraction
of miscarriages, and about 40 % of premature births [33-
36]. Pronounced hemorrhaging and necrosis has been
described during infection of the placenta by some patho-
gens, under conditions where direct fetal damage is not
observed [37,38]. It is conceivable that stimulation of
TNFα secretion by necrotic cells in the placenta may be
one of the triggers for embryo loss. Elevated levels of
TNFα in the environment of the embryo has been associ-
ated with early embryo loss. Stress, which can trigger abor-
tions, also increases the levels of TNFα, and leukocytes
producing TNFα are present in the uterus and placenta. In
spontaneously aborting mice, an increased expression of
TNFα is observed mainly in uterine and trophoblast cells,
and the same cells display enhanced expression of the
TNFα receptor [39].
In mice, during infection with bacteria such as Listeria
monocytogenes  or  Chlamydia trachomatis, maternal neu-
trophils are recruited to the fetomaternal interface and act
as the main immune effector cells against the bacteria. The
macrophage growth factor, colony stimulating factor
(CSF)-1, is produced in large quantities by the uterine epi-
thelium during pregnancy, and induces trophoblasts to
synthesize neutrophil chemoattractants, cytokine-
induced neutrophil chemoattractant (KC) (CXCL1), and
macrophage inflammatory protein (MIP)-2 (CXCL2) [40]
(Fig. 3). In the absence of CSF-1, neutrophils are not
recruited and bacterial infection is unrestrained, leading
to fetal demise. In parallel, the macrophage migration
inhibitory factor (MIF), which is expressed in the human
endometrium in early pregnancy, inhibits NK cell-medi-
ated cytolysis and could thus contribute to immune
privilege at the feto-maternal interface. Conversely, MIF
also stimulates macrophage phagocytosis and secretion of
TNFα and IL-1β, which could lead to recruitment and
maintenance of a pool of activated phagocytes in the
endometrium [41].
The Toll-like receptors TLR2 and TLR4 play different roles
in pathogen recognition. TLR4 is stimulated by LPS, the
most proinflammatory cell wall component of Gram-neg-
ative bacteria, while TLR2 has a broader role as a pattern
recognition receptor for a variety of microbes and Gram-
positive ligands [42]. Consistent with the pattern recogni-
tion preferences of TLR, mutations in the TLR4 receptor
predispose humans to develop septic shock with Gram-
negative bacteria [43]. TLR2 and TLR4 are expressed in the
placenta, mainly in the villous and intermediate trophob-
lasts (Fig. 2), and incubation of placenta cultures with LPS
induces IL-6 and IL-8 cytokine production [44]. At the
same time, urogenital infection caused by Gram-negative
bacteria is a known risk factor for premature births, and
TLR4 mutations are associated with an increased risk of
premature birth [43]. Thus, TLR mutations are detrimen-
tal to the outcome of pregnancy when expressed in the
maternal immune system.
Shifting the immune response toward the Th2 pattern (IL-
4, IL-5, IL-6) may benefit the fetus, whereas development
of pro-inflammatory Th1 cells (secreting IL-2, IFNγ,
TNFα) may be harmful. This view is supported by studies
on different mouse strains infected by Leishmania major
during pregnancy, which have shown that the Th1 anti-
infectious response (spontaneous in C57B1/6 mice) is
associated with some increases in fetal resorption and
implantation failure rates [45]. In the BALB/c strain char-
acterized by a Th2 (non-protective) response to infection,
fetal resorption and implantation failure rates were unaf-
fected. Conversely, in C57B1/6 mice, pregnancy was asso-
ciated with decreased resistance to infection, decreased
IFN-γ production, and increased levels of Th2 cytokines.
The maternal decidua also has an expanded population of
Vα 14 NKT lymphocytes, which as in other tissues can be
stimulated with α-galactosylceramide (α-GalCer) [46].
NKT cells can lyse infected or stressed cells with a pore-
forming protein (perforin) and secrete inflammatory
Cross-talk between fetal trophoblast and maternal macro- phages and neutrophils during placental infection by Listeria Figure 3
Cross-talk between fetal trophoblast and maternal macro-
phages and neutrophils during placental infection by Listeria. 
MΦ: macrophage; CSF-1: colony stimulating factor 1; KC: 
cytokine-induced neutrophil chemoattractant; (MIP)-2: mac-
rophage inflammatory protein-2.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/121
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cytokines. NKT cells can also be stimulated by glycosyl-
phosphatidylinositols derived from protozoan parasites
known to provoke abortion, such as Leishmania mexicana,
Plasmodium falciparum, and Trypanosoma brucei.
Interestingly, stimulation of pregnant mice with α-GalCer
induces abortion through a mechanism requiring NKT
cell-mediated perforin-dependent killing and IFNγ and
TNFα secretion, and histological inspection showed that
embryonic trophoblasts die selectively following α-Gal-
Cer treatment (Fig. 4) [47]. NKT cells recognize glycolip-
ids presented by the MHC-related molecule, CD1d, which
is present on human trophoblasts [48-50]. However,
direct interaction between NKT cells and CD1d in the pla-
centa has not been demonstrated, and it is not known
whether the microbial pathogens may still induce abor-
tion in CD1d-deficient mice.
Conclusion
Recent research on the mechanisms leading to abortion or
premature birth have focused increasingly on the role
played by the innate immune system. A Th2 cytokine pro-
file favors successful pregnancy, while production of Th1
inflammatory cytokines and complement activation
result in higher rates of abortion. Approximately 10 % of
all births are preterm, and the incidence of preterm birth
is increasing and remains the main cause of perinatal mor-
bidity and mortality. Given that preterm births account
for 70 % of perinatal mortality and nearly half of long-
term neurologic morbidity [33], clinical intervention that
could decrease the risk of inflammation during pregnancy
would also contribute to the well-being of the children
who are born. Although one could conceivably envision
the use of therapeutic agents that interfere with comple-
ment activation or modulate TLR-dependent inflamma-
tion, the main challenge will be to develop a strategy that
attenuates inflammatory responses, without jeopardizing
the mother's ability to ward off microbial infections.
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